# BPC-157 TB-500 Dosage in the Research Literature: Routes, Reconstitution, Half-Life

> BPC-157 TB-500 dosage as documented in the research literature — the animal-model doses for each constituent, oral versus injectable routes, reconstitution handling, and why no validated human blend dose exists.

Animal-model doses, the routes studied, reconstitution and half-life — described as research handling, never as human guidance. No validated blend dose exists.

## BPC-157 TB-500 dosage in the research literature

There is no validated dose for the BPC-157 TB-500 blend. No peer-reviewed combination dose-finding study exists, and [the combination rationale and synergy claim](/research) has never been tied to a defined ratio or endpoint [11]. What the literature does contain are doses for each constituent, studied separately, almost entirely in animals. These are reported here as research-handling context, not as human guidance.

For the BPC-157 component, rodent studies commonly express dose per body weight, frequently around `10 microg/kg` and `10 ng/kg`; gastric-ulcer cytoprotection has been studied at `400-800 ng/kg` in rats [1]. For the TB-500 / Thymosin Beta-4 component, the range is wide: `2-18 mg/kg` intraperitoneally in a rat embolic-stroke dose-response study (with the optimal effect modeled near `3.75 mg/kg`, and `18 mg/kg` giving no benefit), and `150 microg` twice weekly intraperitoneally for six months in the mdx muscular-dystrophy study [13][9].

Human single-agent reference points exist only for full-length Thymosin Beta-4, not the blend and not the 7-mer: intravenous Thymosin Beta-4 was well tolerated up to `1260 mg` in one Phase 1 study, and to `25 microg/kg` single or `5 microg/kg` daily for ten days in a 2021 first-in-human study [12]. Community "loading then maintenance" blend protocols have no controlled-trial basis.

### How do you cycle BPC-157 and TB-500?

No controlled human cycling protocol exists. Community "loading then maintenance" schemes are not validated [12]. A rat embolic-stroke study found Thymosin Beta-4 dosing non-monotonic — a higher dose gave no benefit — which undermines "more is better" loading rationales for the blend [13].

## Oral versus injectable routes in the research record

The routes studied differ by constituent and by question. The predominant routes in the underlying rodent efficacy studies were intraperitoneal for both peptides [1][13]. Local, intra-lesional, and topical routes appear in individual-compound wound and tendon models [1][4]. Intravenous was used in the human Phase 1 work on full-length Thymosin Beta-4 and a BPC-157 IV safety pilot [12].

On the "bpc 157 tb 500 oral" question specifically: BPC-157 is studied as a "stable gastric" peptide and has been administered perorally in animal models [1]. The TB-500 heptapeptide has no comparable oral PK characterization. Oral blend products are marketed, but they lack validated pharmacokinetics, and the subcutaneous and intramuscular routes common in community use do not come from controlled human efficacy trials [6].

## Reconstitution and injection in research handling

Both constituents are supplied as lyophilized (freeze-dried) powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated [6]. A common community practice is to reconstitute the two peptides separately or in a shared vial. The handling caveat is the point: product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated "Wolverine" material are not guaranteed, which compounds the existing identity caveat around TB-500 — fragment versus full-length Thymosin Beta-4 [6][7].

## Half-life and pharmacokinetics

There is no validated human pharmacokinetic profile for either constituent at research-use doses, and none for the blend. What exists is fragmentary and per-compound.

---

A two-lane dispatch manifest on the BPC-157 and TB-500 record — every constituent finding logged to its study, every blend-level claim cleared as no-human-data, with no clinic behind the console and nothing here routed for sale.